Thalidomide-NH-(CH2)2-NH2 TFA is a functionalized thalidomide analog optimized for use as an E3 ligase ligand in PROTAC (Proteolysis Targeting Chimera) drug discovery. Featuring an aminoethyl linker at the 4-amino position, this compound has enhanced reactivity and ease of conjugation to target-specific ligands, enabling efficient synthesis of cereblon (CRBN)-recruiting PROTAC molecules. Thalidomide-NH-(CH2)2-NH2 TFA is supplied as a trifluoroacetic acid (TFA) salt, improving solubility and handling. Widely utilized in targeted protein degradation research, this reagent supports the design of next-generation therapeutics by harnessing the ubiquitin-proteasome system for selective protein knockdown.
Structure of 1957235-67-4
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
Thalidomide-NH-(CH2)2-NH2 TFA is a functionalized thalidomide derivative designed for use as a Cereblon (CRBN) E3 ligase ligand in targeted protein degradation strategies such as PROTACs. This molecule features a primary amine-terminated ethylene linker attached to the thalidomide core via a stable amide bond, with the TFA (trifluoroacetic acid) salt form ensuring improved solubility and handling. Innovations in ligand design like this compound have enabled more effective conjugation and higher versatility in constructing degraders for chemical biology and drug discovery applications.
Mechanism
Thalidomide-NH-(CH2)2-NH2 TFA binds specifically to the Cereblon (CRBN) component of the CUL4-CRBN E3 ubiquitin ligase complex, serving as the E3 ligase-recruiting element in bifunctional molecules. The ethylene diamine linker with a terminal primary amine offers a convenient site for chemical conjugation to a target protein ligand via standard coupling reactions. Once incorporated into a PROTAC, the molecule bridges CRBN and the target protein, leading to targeted ubiquitination and proteasomal degradation of the protein of interest.
Applications
Thalidomide-NH-(CH2)2-NH2 TFA is extensively employed as a key building block for the synthesis of CRBN-based PROTACs and molecular glue degraders. Its amine-terminated linker allows facile functionalization, enabling rapid generation of diverse degrader libraries for structure-activity relationship (SAR) studies and hit-to-lead optimization. Typical applications include:
• Development of custom CRBN-recruiting PROTACs for drug discovery and target validation
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.